Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis

Lajos Pusztai, Giuseppe Viale, Catherine M. Kelly, Clifford A. Hudis

Research output: Contribution to journalArticle

Abstract

Discordance in estrogen receptor and human epidermal growth factor receptor 2 receptor status between the primary tumor and recurrence is frequently reported in the literature. This is frequently interpreted as evidence for a change in the biology of breast cancer during the course of the disease. This commentary discusses some of the caveats of this interpretation. Discordant receptor results can be caused by any of 3 factors: (a) a genuine switch in the biology of the disease, (b) sampling error in focally receptor-positive cancers, and (c) limited accuracy and reproducibility of receptor assays. The relative contribution of each of these factors to discordant results is unknown. A switch in molecular class between primary and recurrent cancer (or residual cancer after therapy) appears to be a rare event based on the available limited molecular profiling data. Small pockets of strongly focally receptorpositive tumor nests in a larger receptor-negative cancer are also relatively infrequently seen. Discordance resulting from inherent limitations in assay reproducibility is evident from the frequently discordant receptor results even when the same samples are assessed in different laboratories (e.g., central versus local laboratory). A repeat tumor biopsy is clearly justified when it is suspected, on clinical grounds, that the original receptor results may have been false negative or when the diagnosis of metastatic disease is in question. However, routine repeat biopsy for receptor re-evaluation does not necessarily improve diagnostic accuracy and have a potential to harm through a false-negative result. For patients with clinical courses consistent with hormone responsiveness, or with prior positive hormone receptor results, a course of endocrine therapy is reasonable regardless of the most recent hormone receptor assay result.

Original languageEnglish
Pages (from-to)1164-1168
Number of pages5
JournalThe oncologist
Volume15
Issue number11
DOIs
Publication statusPublished - 2010

Fingerprint

Estrogens
Breast Neoplasms
Neoplasm Metastasis
Neoplasms
Hormones
Biopsy
Selection Bias
Residual Neoplasm
Estrogen Receptors
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. / Pusztai, Lajos; Viale, Giuseppe; Kelly, Catherine M.; Hudis, Clifford A.

In: The oncologist, Vol. 15, No. 11, 2010, p. 1164-1168.

Research output: Contribution to journalArticle

Pusztai, Lajos ; Viale, Giuseppe ; Kelly, Catherine M. ; Hudis, Clifford A. / Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. In: The oncologist. 2010 ; Vol. 15, No. 11. pp. 1164-1168.
@article{ba2a7b3669ec444c82932d992bc12dd1,
title = "Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis",
abstract = "Discordance in estrogen receptor and human epidermal growth factor receptor 2 receptor status between the primary tumor and recurrence is frequently reported in the literature. This is frequently interpreted as evidence for a change in the biology of breast cancer during the course of the disease. This commentary discusses some of the caveats of this interpretation. Discordant receptor results can be caused by any of 3 factors: (a) a genuine switch in the biology of the disease, (b) sampling error in focally receptor-positive cancers, and (c) limited accuracy and reproducibility of receptor assays. The relative contribution of each of these factors to discordant results is unknown. A switch in molecular class between primary and recurrent cancer (or residual cancer after therapy) appears to be a rare event based on the available limited molecular profiling data. Small pockets of strongly focally receptorpositive tumor nests in a larger receptor-negative cancer are also relatively infrequently seen. Discordance resulting from inherent limitations in assay reproducibility is evident from the frequently discordant receptor results even when the same samples are assessed in different laboratories (e.g., central versus local laboratory). A repeat tumor biopsy is clearly justified when it is suspected, on clinical grounds, that the original receptor results may have been false negative or when the diagnosis of metastatic disease is in question. However, routine repeat biopsy for receptor re-evaluation does not necessarily improve diagnostic accuracy and have a potential to harm through a false-negative result. For patients with clinical courses consistent with hormone responsiveness, or with prior positive hormone receptor results, a course of endocrine therapy is reasonable regardless of the most recent hormone receptor assay result.",
author = "Lajos Pusztai and Giuseppe Viale and Kelly, {Catherine M.} and Hudis, {Clifford A.}",
year = "2010",
doi = "10.1634/theoncologist.2010-0059",
language = "English",
volume = "15",
pages = "1164--1168",
journal = "Oncologist",
issn = "1083-7159",
publisher = "Wiley Blackwell",
number = "11",

}

TY - JOUR

T1 - Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis

AU - Pusztai, Lajos

AU - Viale, Giuseppe

AU - Kelly, Catherine M.

AU - Hudis, Clifford A.

PY - 2010

Y1 - 2010

N2 - Discordance in estrogen receptor and human epidermal growth factor receptor 2 receptor status between the primary tumor and recurrence is frequently reported in the literature. This is frequently interpreted as evidence for a change in the biology of breast cancer during the course of the disease. This commentary discusses some of the caveats of this interpretation. Discordant receptor results can be caused by any of 3 factors: (a) a genuine switch in the biology of the disease, (b) sampling error in focally receptor-positive cancers, and (c) limited accuracy and reproducibility of receptor assays. The relative contribution of each of these factors to discordant results is unknown. A switch in molecular class between primary and recurrent cancer (or residual cancer after therapy) appears to be a rare event based on the available limited molecular profiling data. Small pockets of strongly focally receptorpositive tumor nests in a larger receptor-negative cancer are also relatively infrequently seen. Discordance resulting from inherent limitations in assay reproducibility is evident from the frequently discordant receptor results even when the same samples are assessed in different laboratories (e.g., central versus local laboratory). A repeat tumor biopsy is clearly justified when it is suspected, on clinical grounds, that the original receptor results may have been false negative or when the diagnosis of metastatic disease is in question. However, routine repeat biopsy for receptor re-evaluation does not necessarily improve diagnostic accuracy and have a potential to harm through a false-negative result. For patients with clinical courses consistent with hormone responsiveness, or with prior positive hormone receptor results, a course of endocrine therapy is reasonable regardless of the most recent hormone receptor assay result.

AB - Discordance in estrogen receptor and human epidermal growth factor receptor 2 receptor status between the primary tumor and recurrence is frequently reported in the literature. This is frequently interpreted as evidence for a change in the biology of breast cancer during the course of the disease. This commentary discusses some of the caveats of this interpretation. Discordant receptor results can be caused by any of 3 factors: (a) a genuine switch in the biology of the disease, (b) sampling error in focally receptor-positive cancers, and (c) limited accuracy and reproducibility of receptor assays. The relative contribution of each of these factors to discordant results is unknown. A switch in molecular class between primary and recurrent cancer (or residual cancer after therapy) appears to be a rare event based on the available limited molecular profiling data. Small pockets of strongly focally receptorpositive tumor nests in a larger receptor-negative cancer are also relatively infrequently seen. Discordance resulting from inherent limitations in assay reproducibility is evident from the frequently discordant receptor results even when the same samples are assessed in different laboratories (e.g., central versus local laboratory). A repeat tumor biopsy is clearly justified when it is suspected, on clinical grounds, that the original receptor results may have been false negative or when the diagnosis of metastatic disease is in question. However, routine repeat biopsy for receptor re-evaluation does not necessarily improve diagnostic accuracy and have a potential to harm through a false-negative result. For patients with clinical courses consistent with hormone responsiveness, or with prior positive hormone receptor results, a course of endocrine therapy is reasonable regardless of the most recent hormone receptor assay result.

UR - http://www.scopus.com/inward/record.url?scp=78649959817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649959817&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2010-0059

DO - 10.1634/theoncologist.2010-0059

M3 - Article

C2 - 21041379

AN - SCOPUS:78649959817

VL - 15

SP - 1164

EP - 1168

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 11

ER -